Literature DB >> 22442316

Molecular detection of rifabutin-susceptible Mycobacterium tuberculosis.

Huang-Yao Chen1, Ming-Chih Yu, Wei-Lun Huang, Mei-Hua Wu, Yung-Lin Chang, Chien-Rai Che, Ruwen Jou.   

Abstract

Rapid assays are still needed to detect rifabutin (RFB) susceptibility for proper tuberculosis treatment. To assess the use of the GenoType MTBDRplus assay and subsequent rpoB gene sequencing on detection of RFB susceptibility, we analyzed 800 multidrug-resistant Mycobacterium tuberculosis isolates, and 13% (104/800) were RFB susceptible. Of the 104 RFB-susceptible isolates, 71 (68.3%) isolates were rapidly identified using two molecular assays, while the remaining isolates could be determined using conventional drug-susceptibility testing according to the clinician's decision.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22442316      PMCID： PMC3372129          DOI： 10.1128/JCM.00652-12

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  11 in total

1.  Mutations in the beginning of the rpoB gene can induce resistance to rifamycins in both Helicobacter pylori and Mycobacterium tuberculosis.

Authors:  M Heep; U Rieger; D Beck; N Lehn
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

2.  Rapid diagnosis of drug-resistant TB using line probe assays: from evidence to policy.

Authors:  Daphne I Ling; Alice A Zwerling; Madhukar Pai
Journal:  Expert Rev Respir Med       Date:  2008-10       Impact factor: 3.772

3.  Comparison of rifabutin susceptibility and rpoB mutations in multi-drug-resistant Mycobacterium tuberculosis strains by DNA sequencing and the line probe assay.

Authors:  Shiomi Yoshida; Katsuhiro Suzuki; Tomotada Iwamoto; Kazunari Tsuyuguchi; Motohisa Tomita; Masaji Okada; Mitsunori Sakatani
Journal:  J Infect Chemother       Date:  2010-03-31       Impact factor: 2.211

4.  Genetic diversity of multidrug-resistant Mycobacterium tuberculosis isolates and identification of 11 novel rpoB alleles in Taiwan.

Authors:  Ruwen Jou; Huang-Yau Chen; Chen-Yuan Chiang; Ming-Chih Yu; Ih-Jen Su
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

5.  Comparison of two commercial assays for the characterization of rpoB mutations in Mycobacterium tuberculosis and description of new mutations conferring weak resistance to rifampicin.

Authors:  Yolande Hauck; Michel Fabre; Gilles Vergnaud; Charles Soler; Christine Pourcel
Journal:  J Antimicrob Chemother       Date:  2009-06-11       Impact factor: 5.790

6.  Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia.

Authors:  V Sintchenko; W K Chew; P J Jelfs; G L Gilbert
Journal:  Pathology       Date:  1999-08       Impact factor: 5.306

7.  Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey.

Authors:  G Senol; A Erbaycu; A Ozsöz
Journal:  J Chemother       Date:  2005-08       Impact factor: 1.714

8.  Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis.

Authors:  Wei-Lun Huang; Huang-Yau Chen; Yuh-Min Kuo; Ruwen Jou
Journal:  J Clin Microbiol       Date:  2009-06-03       Impact factor: 5.948

9.  In-vitro and intracellular activity of rifabutin on drug-susceptible and multiple drug-resistant (MDR) tubercle bacilli.

Authors:  J Luna-Herrera; M V Reddy; P R Gangadharam
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

10.  [Cross-resistance between rifampicin and rifabutin among multi-drug resistant Mycobacterium tuberculosis strains].

Authors:  Kinuyo Chikamatsu; Kazue Mizuno; Hiroyuki Yamada; Satoshi Mitarai
Journal:  Kekkaku       Date:  2009-09
View more
  9 in total

1.  The potential use of rifabutin for treatment of patients diagnosed with rifampicin-resistant tuberculosis.

Authors:  Michael G Whitfield; Robin M Warren; Vanessa Mathys; Lesley Scott; Elise De Vos; Wendy Stevens; Elizabeth M Streicher; Guido Groenen; Frederick A Sirgel; Annelies Van Rie
Journal:  J Antimicrob Chemother       Date:  2018-10-01       Impact factor: 5.790

2.  Profiling of rpoB mutations and MICs for rifampin and rifabutin in Mycobacterium tuberculosis.

Authors:  F B Jamieson; J L Guthrie; A Neemuchwala; O Lastovetska; R G Melano; C Mehaffy
Journal:  J Clin Microbiol       Date:  2014-04-16       Impact factor: 5.948

3.  Rifabutin and rifampin resistance levels and associated rpoB mutations in clinical isolates of Mycobacterium tuberculosis complex.

Authors:  Zenda L Berrada; Shou-Yean Grace Lin; Timothy C Rodwell; Duylinh Nguyen; Gisela F Schecter; Lucy Pham; J Michael Janda; Wael Elmaraachli; Antonino Catanzaro; Edward Desmond
Journal:  Diagn Microbiol Infect Dis       Date:  2016-02-03       Impact factor: 2.803

4.  Disputed rpoB Mutations in Mycobacterium tuberculosis and Tuberculosis Treatment Outcomes.

Authors:  Wan-Hsuan Lin; Wei-Ting Lee; Hsing-Yuan Tsai; Ruwen Jou
Journal:  Antimicrob Agents Chemother       Date:  2021-06-17       Impact factor: 5.191

5.  A Comparison of the Sensititre MycoTB Plate, the Bactec MGIT 960, and a Microarray-Based Molecular Assay for the Detection of Drug Resistance in Clinical Mycobacterium tuberculosis Isolates in Moscow, Russia.

Authors:  Elena Y Nosova; Danila V Zimenkov; Anastasia A Khakhalina; Alexandra I Isakova; Ludmila Y Krylova; Marina V Makarova; Ksenia Y Galkina; Maria A Krasnova; Svetlana G Safonova; Vitaly I Litvinov; Dmitry A Gryadunov; Elena M Bogorodskaya
Journal:  PLoS One       Date:  2016-11-30       Impact factor: 3.240

6.  Correlation of rpoB Mutations with Minimal Inhibitory Concentration of Rifampin and Rifabutin in Mycobacterium tuberculosis in an HIV/AIDS Endemic Setting, South Africa.

Authors:  Ivy Rukasha; Halima M Said; Shaheed V Omar; Hendrik Koornhof; Andries W Dreyer; Alfred Musekiwa; Harry Moultrie; Anwar A Hoosen; Gilla Kaplan; Dorothy Fallows; Nazir Ismail
Journal:  Front Microbiol       Date:  2016-12-05       Impact factor: 5.640

7.  Global access of rifabutin for the treatment of tuberculosis - why should we prioritize this?

Authors:  Neesha Rockwood; Maddalena Cerrone; Melissa Barber; Andrew M Hill; Anton L Pozniak
Journal:  J Int AIDS Soc       Date:  2019-07       Impact factor: 5.396

8.  Whole-Genome Sequencing for Resistance Level Prediction in Multidrug-Resistant Tuberculosis.

Authors:  Jinli Li; Tingting Yang; Chuangyue Hong; Zheng Yang; Likai Wu; Qian Gao; Hui Yang; Weiguo Tan
Journal:  Microbiol Spectr       Date:  2022-06-06

9.  The rationale for using rifabutin in the treatment of MDR and XDR tuberculosis outbreaks.

Authors:  Frederick A Sirgel; Robin M Warren; Erik C Böttger; Marisa Klopper; Thomas C Victor; Paul D van Helden
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.